Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB

As tumor mutational burden (TMB) has been approved as a predictive biomarker for immune checkpoint inhibitors (ICIs), next-generation sequencing (NGS) TMB panels are being increasingly used clinically. However, only a few of them have been validated in clinical trials or authorized by administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Meng-Ta, Wang, Yeh-Han, Li, Chien-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103036/
https://www.ncbi.nlm.nih.gov/pubmed/35563486
http://dx.doi.org/10.3390/ijms23095097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103036/
https://www.ncbi.nlm.nih.gov/pubmed/35563486
http://dx.doi.org/10.3390/ijms23095097

Ejemplares similares